Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic (detectable HCV Ribonucleic acid (RNA) more than 6 months prior screening or histological diagnosis based on liver biopsy or fibroscan) HCV infection genotype 1 with HCV RNA level greater than 1,000 IU/mL~* Confirmed diagnosis of HIV-1 infection greater than 6 months before the screening visit~* CD4 count greater than 300 cells/mm3 at screening and no value less than 200 cells/mm3 within 6 months of screening visit~* HIV-1 RNA undetectable by an ultrasensitive assay at least once within 90 days of the screening visit~* No HIV RNA values greater than 200 copies/mL within 6 months of the screening visit~* Currently taking one of the permitted anti-HIV regimens for greater than or equal to12 weeks~Exclusion Criteria:~* Anticipated need to switch anti-HIV regimen from screening through the Telaprevir treatment period~* Infection or co-infection with HCV other than genotype 1~* Contraindication to the administration of Peg-IFN-alfa or RBV~* Hepatitis B virus (HBV) co-infection~* Acute or active condition of HIV-associated opportunistic infection within 6 months of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Telaprevir plus Pegylated-Interferon-alfa-2a /ribavirin (RBV) (Type: EXPERIMENTAL): All patients who will receive 12 weeks of treatment with telaprevir 750 mg q8h except for patients on efavirenz will receive 1125 mg every 8 hours (q8h) in combination with Pegylated-Interferon-alfa-2a (Peg-IFN-alfa-2a) 180 μg/week and RBV 800 mg/day. At Week 12, telaprevir dosing will end and the patients will continue on Peg-IFN-alfa-2a and RBV.

Based on this trial design, predict the completion outcome and termination type (if applicable).